Healthcare / BiotechnologyKOSDAQKR
$19220.00
+510.00 (+2.73%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-3.8B · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$218.5B
P/E
46.5x
↑EV/EBITDA
23.9x
↑ROE
10.1%
↑Gross Margin
63.5%
↑Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+14.7%
FCF CAGR
-46.6%
FCF margin
1.7%
FCF / Net income
0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.72B · net income $4.64B · FCF $546.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32.72B | $32.72B | $24.55B | $15.70B | $21.67B |
| Net Income | $4.64B | $4.64B | $-9.33B | $-6.28B | $-3.77B |
| EBITDA | $8.54B | $8.54B | $-4.06B | $75.1M | $976.5M |
| EPS | 413.00 | 413.00 | -897.00 | -631.00 | -379.00 |
| Gross Margin | 63.5% | 63.5% | 51.7% | 52.6% | 60.2% |
| Operating Margin | 15.4% | 15.4% | -20.1% | -14.2% | 3.0% |
| Net Margin | 14.2% | 14.2% | -38.0% | -40.0% | -17.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.22 | 0.22 | 0.50 | 0.77 | 0.67 |
| Current Ratio | 3.35 | 3.35 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $546.9M | $546.9M | $-3.78B | $-9.64B | $3.59B |
| Returns | |||||
| ROE | 10.1% | 10.1% | -28.9% | -21.8% | -11.4% |
| Valuation | |||||
| P/E | 46.54 | 46.54 | — | — | — |
| EV/EBITDA | 23.88 | 23.88 | — | 3111.81 | 176.78 |
| P/B | 4.71 | 4.71 | 5.30 | 8.06 | 5.38 |
| Growth & Yield | |||||
| Revenue Growth | 33.3% | 33.3% | 56.3% | -27.5% | — |
| EPS Growth | 146.0% | 146.0% | -42.2% | -66.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
60.4%
EPS terminal req.
$1705.45
Spread vs growth
85.6%
5Y implied EPS CAGR
38.0%
EPS terminal req.
$2063.60
Spread vs growth
108.1%
10Y implied EPS CAGR
23.2%
EPS terminal req.
$3323.45
Spread vs growth
122.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-897.00 → 413.00
Residual
-33.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.